Skip to main content
رجوع
VTRS logo

Viatris Inc.

جودة البيانات: 100%
VTRS
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 13.29
▲ KWD 0.09 (0.68%)
القيمة السوقية: 15.31B
نطاق اليوم
KWD 13.20 KWD 13.47
نطاق 52 أسبوعًا
KWD 6.85 KWD 16.47
حجم التداول
8,683,606
متوسط 50 يوم / 200 يوم
KWD 14.22 / KWD 11.17
الإغلاق السابق
KWD 13.20

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -4.4 0.4
P/B 1.0 2.9
ROE % -21.1 3.7
Net Margin % -24.6 3.9
Rev Growth 5Y % -5.4 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

Hold
KWD 15.250 +14.7%
Low: KWD 12.000 High: KWD 18.000
مكرر الربحية المستقبلي
5.4
ربحية السهم المستقبلية
KWD 2.449
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
15 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.000
KWD 0.000 – KWD 0.000
15 B 0
FY2028 KWD 3.253
KWD 1.485 – KWD 5.021
15 B 2
FY2027 KWD 2.667
KWD 2.358 – KWD 2.770
15 B 5

النقاط الرئيسية

Revenue declined -5.44% annually over 5 years
Generating 1.94B in free cash flow
Capital efficient — spends only 2.65% of revenue on capex

النمو

Revenue Growth (5Y)
-5.44%
Revenue (1Y)-2.98%
Earnings (1Y)N/A
FCF Growth (3Y)-8.72%

الجودة

Return on Equity
-21.08%
ROIC-6.79%
Net Margin-24.58%
Op. Margin-18.62%

الأمان

Debt / Equity
1.00
Current Ratio1.30
Interest Coverage-5.65

التقييم

P/E Ratio
-4.35
P/B Ratio1.04
EV/EBITDAN/A
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2.98% Revenue Growth (3Y) -3.72%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -5.44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14.30B Net Income (TTM) -3.51B
ROE -21.08% ROA -9.45%
Gross Margin 35.06% Operating Margin -18.62%
Net Margin -24.58% Free Cash Flow (TTM) 1.94B
ROIC -6.79% FCF Growth (3Y) -8.72%
Safety
Debt / Equity 1.00 Current Ratio 1.30
Interest Coverage -5.65 Dividend Yield 0.04%
Valuation
P/E Ratio -4.35 P/B Ratio 1.04
P/S Ratio 1.07 PEG Ratio -0.01
EV/EBITDA N/A Dividend Yield 0.04%
Market Cap 15.31B Enterprise Value 28.66B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14.30B 14.74B 15.43B 16.26B 17.89B
Net Income -3.51B -634.20M 54.70M 2.08B -1.27B
EPS (Diluted) -3.00 -0.53 0.05 1.71 -1.05
Gross Profit 5.01B 5.62B 6.44B 6.50B 5.58B
Operating Income -2.66B 10.10M 766.20M 1.61B -34.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 37.19B 41.50B 47.69B 50.02B 54.84B
Total Liabilities 22.48B 22.87B 27.22B 28.95B 34.35B
Shareholders' Equity 14.71B 18.64B 20.47B 21.07B 20.49B
Total Debt 14.70B 14.31B 18.37B 19.53B 23.36B
Cash & Equivalents 1.35B 734.80M 991.90M 1.26B 701.20M
Current Assets 9.22B 9.52B 12.98B 10.64B 10.90B
Current Liabilities 7.09B 5.78B 7.78B 6.75B 9.88B